Sit Investment Associates Has Cut Sarepta Therapeutics (SRPT) Position; Auris Medical Holding AG (EARS) Had 3 Analysts Last Week

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Among 3 analysts covering Auris Medical Holding AG (NASDAQ:EARS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Auris Medical Holding AG has $8 highest and $4.5000 lowest target. $5.83’s average target is 264.38% above currents $1.6 stock price. Auris Medical Holding AG had 4 analyst reports since March 15, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, March 15 by Jefferies. As per Friday, August 19, the company rating was maintained by Needham. Roth Capital initiated the shares of EARS in report on Friday, June 30 with “Buy” rating. See Auris Medical Holding AG (NASDAQ:EARS) latest ratings:

Sit Investment Associates Inc decreased Sarepta Therapeutics Inc (SRPT) stake by 17.61% reported in 2017Q4 SEC filing. Sit Investment Associates Inc sold 5,850 shares as Sarepta Therapeutics Inc (SRPT)’s stock rose 36.45%. The Sit Investment Associates Inc holds 27,375 shares with $1.52 million value, down from 33,225 last quarter. Sarepta Therapeutics Inc now has $4.81 billion valuation. The stock increased 3.29% or $2.36 during the last trading session, reaching $74.09. About 1.11 million shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since March 31, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics has $108 highest and $4 lowest target. $69.84’s average target is -5.74% below currents $74.09 stock price. Sarepta Therapeutics had 113 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Equal-Weight” rating on Wednesday, March 21 by Morgan Stanley. RBC Capital Markets maintained it with “Buy” rating and $64.0 target in Monday, October 2 report. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Wednesday, August 26 by Roth Capital. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Piper Jaffray on Friday, February 9. On Thursday, March 2 the stock rating was upgraded by Leerink Swann to “Outperform”. The firm earned “Buy” rating on Wednesday, June 28 by Credit Suisse. The rating was maintained by Piper Jaffray on Tuesday, July 25 with “Buy”. Morgan Stanley maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Wednesday, January 4. Morgan Stanley has “Equal-Weight” rating and $33 target. As per Wednesday, June 21, the company rating was maintained by RBC Capital Markets. The stock has “Buy” rating by RBC Capital Markets on Monday, January 22.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on April, 26. They expect $-0.32 EPS, up 56.16% or $0.41 from last year’s $-0.73 per share. After $-0.37 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -13.51% EPS growth.

Since October 3, 2017, it had 0 insider buys, and 1 sale for $575,000 activity. Shares for $575,000 were sold by Ruff Shamim on Tuesday, October 3.

Investors sentiment decreased to 1.22 in Q4 2017. Its down 1.66, from 2.88 in 2017Q3. It dropped, as 27 investors sold SRPT shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported. Point72 Asset Management LP accumulated 579,757 shares or 0.14% of the stock. Hightower Advsrs Llc invested in 0.03% or 68,518 shares. Sei Investments Company, a Pennsylvania-based fund reported 32,917 shares. Raymond James Fin Svcs invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Metropolitan Life Insurance has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 18,864 shares. 559,874 were reported by Voya Management Ltd Liability Corp. Financial Bank Of America De invested in 81,428 shares. Gam Holdings Ag, a Switzerland-based fund reported 23,200 shares. California Public Employees Retirement Systems invested in 146,700 shares or 0.01% of the stock. C Worldwide Grp Holdg A S owns 100,478 shares or 0.08% of their US portfolio. Teacher Retirement Of Texas owns 20,528 shares. Brighton Jones Limited Liability Company holds 0.03% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 4,661 shares. Eventide Asset Mgmt holds 0.47% or 161,000 shares in its portfolio. Commercial Bank Of Montreal Can stated it has 85,707 shares or 0% of all its holdings. Morgan Stanley has invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Sit Investment Associates Inc increased Wa/Clay Inflation (WIA) stake by 29,826 shares to 686,501 valued at $8.09M in 2017Q4. It also upped Prudential Short Dur Hi Yld Fd (ISD) stake by 128,982 shares and now owns 194,935 shares. Nuveen Cred Strat Inc Fd Jqc (JQC) was raised too.

The stock decreased 6.43% or $0.11 during the last trading session, reaching $1.6. About 103,434 shares traded. Auris Medical Holding AG (NASDAQ:EARS) has declined 80.78% since March 31, 2017 and is downtrending. It has underperformed by 92.33% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart